

Annual Report 2009-10



Alpa Laboratories Limited

-- PAGE LEFT BLANK --

THE BOARD OF DIRECTORS

Mr. Purushottam R. Patel, Chairman & Managing Director
 Mr. Mahendra Singh Chawla
 Mr. Pravin C. Shah
 Mr. Sampat Lal Chaplot
 Mr. Sharad Chand Lunawat
COMPLIANCE OFFICER
 Mr. Hemant Jain

REGISTERED & CORPORATE OFFICE

33/2, Pigdamber, A.B. Road, Rau
 Indore (M.P.) 453446, India
 Ph: +91-731-429-4567, Fx: +91-731-429-4444, Em: is@alpalabs.com

STATUTORY AUDITORS OF THE COMPANY

M/s. C. H. Padliya & Co., Chartered Accountants

BANKERS

State Bank of Indore
 Yeshwant Niwas Road Branch
 Indore (M.P.) 452001

REGISTRAR & TRANSFER AGENT

Bigshare Services Private Limited
 E/2 Ansa Industrial Estate, Saki Vihar Road
 Andheri (East), Mumbai 400072

CONTENTS

Notice for the 22 nd AGM.....	1
Directors' Report.....	3
Report on Corporate Governance.....	7
Auditors' Certificate on Corporate Governance.....	11
Auditors' Report.....	11
Balance Sheet.....	14
Profit & Loss Account.....	15
Schedules.....	17
Proxy Form for the AGM.....	Inside Back Cover
Attendance Slip for the AGM.....	Inside Back Cover

NOTICE TO SHAREHOLDERS

Notice is hereby given that the 22nd Annual General Meeting of the members of the Company will be held on Thursday, the 09th Day of September, 2010 at the registered office of the Company at 33/2 Pigdamber, A.B. Road, Rau, Dist. Indore (M. P.) 453446 at 11:45 AM to transact the following business:

ORDINARY BUSINESS

1. To receive, consider and adopt the audited Balance Sheet as at March 31st, 2010 and the Profit & Loss Account for the year ended on that date, together with the Report of the Directors and the Auditors thereon.
2. To appoint a director in place of Mr. Mahendra Singh Chawla, who retires by rotation and being eligible, offers himself for re-appointment.
3. To appoint M/s. C. H. Padliya & Co., Chartered Accountants, as the statutory Auditors of the Company, to hold office from the conclusion of this Annual General Meeting until the conclusion of the next Annual General Meeting, at such remuneration as may be determined by the Board of Directors in consultation with the Auditors.

SPECIAL BUSINESS

4. To consider and if thought fit, to pass, with or without modification(s), the following resolution as a special resolution:
"RESOLVED THAT pursuant to Section 60, 61 and all other provisions of the Companies Act, 1956 including any amendment thereto or reenactment thereof Prospectus, the Listing Agreement entered into by the Company with Stock Exchanges where the shares of the Company are listed and in accordance with applicable guidelines, rules & regulations issued by Securities & Exchange Board of India, Government of India or any other relevant authority & clarification issued thereon, from time to time, if any, that the consent of the Company be and is hereby accorded to delegate the power to decide, alter, vary, revise & finalize the utilization of IPO Proceeds to the Board of Directors of the Company.

FURTHER RESOLVED THAT the Board of Directors may take up any new activity/ expense/ financial commitment apart from those mentioned in the Prospectus dated July 19, 2007 and/ or modify the size and scale of capital expansion proposed in the past.

FURTHER RESOLVED THAT the Board of Directors be and are hereby authorized to address any concern, reply any query, decide any issue, answer any query, interpret any term/ phrase, write/ apply to any Government/ statutory Authority, issue any clarification, decide any other matter in this regard in the interest of the Company."

NOTES:

- a. A member entitled to attend and vote at the meeting is also entitled to appoint a proxy to attend and vote on his behalf and such proxy need not be a member of the company.
- b. The proxy form to be effective, should be deposited at the registered office of the company not less than 48 hours before the

commencement of the Annual General Meeting.

- c. The 'Register of Members' and 'Share Transfer Books' will remain closed from Mon , 06th September, 2010 to Thu, 09th September, 2010 (both days inclusive).
- d. Members are requested to notify immediately changes, if any, in their address/ bank mandate to their respective Depository Participants (DPs) in respect of electronic share account and to the Registrar & Share Transfer Agent with all necessary details, in respect of physical share folios.
- e. Nomination facility is available as per the provision of the Companies Act, 1956. Those who wish to avail themselves of this facility may send in their Nomination Forms (Form 2B) either to the Registrar or to the Company at its Registered Office.
- f. At the ensuing general meeting Mr. Mahendra Singh Chawla shall retire by rotation and being eligible, offers himself for re-appointment. Pursuant to Clause 49 of the Listing Agreement, the particulars of Mr. Mahendra Singh Chawla are as follows:
Mr. Mahendra Singh Chawla, aged 68 years, holds a Bachelors Degree in Science from Indore University. He is also an approved manufacturing chemist and is responsible for the overall manufacturing operations. He is also a co-founder of the company. He is not holding any other directorships.

EXPLANATORY STATEMENT PURSUANT TO SECTION 173(2) OF THE COMPANIES ACT, 1956

Item No. 4

Through Initial Public Offer (IPO) of the company in July 2007, the Company raised Rs. 6106.81 lacs for the following main objects as per the Prospectus issued under Section 67 of the Companies Act, 1956:

- Up-gradation of the existing plant at Pigdamber, Indore and setting up a new plant at Pigdamber, Indore for increasing our production & testing capacities;
- Meeting Margin money working capital requirements;
- General Corporate Purposes;
- Meeting Issue Expenses;

The total cost for the above-mentioned objects as per our Company's estimate was as follows:

S. No.	Particulars	Amount (Rs. in lacs)
1	Capital Expenditure for up-gradation of existing plant and setting up a new plant	6313.16
2	Working Capital requirements	1263.52
3	General Corporate Purposes	650.97
4	Meeting issue expenses	532.95
	Total Cost of the Project	8760.60

The proposed Means of Finance for the above requirements of the funds was proposed to be met as follows:

S. No	Particulars	Amount (Rs. in lacs)
1	Term Loans	2000.00
2	Promoters Participation	300.60
3	Issue Proceeds	6460.00
	Total Finance	8760.60

The Company has not utilized the money in the time frame proposed in the Prospectus due to various factors mostly due to changes in local government policy, as a matter of business strategy and uncertainty in global & domestic pharmaceutical markets. The Company has partially utilized the funds and proposes to seek flexibility for the balance funds remaining.

The new plant was proposed to be setup in Pigdamber in close proximity to the existing plant, but Pigdamber has been rezoned as "residential" in the new Indore city master plan which could potentially cause contravention of local zoning regulations in very near future. In view of this change in the Indore city master plan, expansion of capacities for certain products has been done at the existing Pigdamber plant (Unit-I) and a new plant (Unit-II) is being set up in newly acquired land measuring 40,000 Sq. Mt. (approximately 10 acres) at the Pithampur Industrial Area which is approximately 30 kilometers from the existing Unit-I. At this time a state of the art, regulated market compliant tablet manufacturing facility focusing on containment products such as hormonal and anti-cancer formulations is in the completion phase at Unit-II. Other dosage form capacities have been expanded at Unit-I.

With the above changes, the proposed cost estimates are as follows:

S. No.	Particulars	Amount (Rs. in lacs)
1	Capital Expenditure for up-gradation of existing plant and setting up a new plant	5157.66
2	Working Capital requirements	1263.52
3	General Corporate Purposes	735.12
4	Meeting issue expenses	791.12
	Total Cost of the Project	7947.42

And the corresponding proposed Means of Finance is as follows:

S. No	Particulars	Amount (Rs. in lacs)
1	Term Loans	1500.00
2	Promoters Participation	340.61
3	Issue Proceeds	6106.81
	Total Finance	7947.42

Accordingly, the Board of Directors may be authorized to utilize the IPO proceeds in any new expenditure head or in any or all of the utilization purposes stated in the Prospectus dated July 19, 2007 e.g. Company may use any of the amount of the remaining IPO proceeds to meet its working capital requirements, up-gradation of existing facilities & other general corporate purposes as allowed under the applicable laws. The resolution is being proposed to the Members for consideration and if deemed fit for approval as a part of good corporate governance practices that the company endeavors to follow.

None of the Directors of the Company are in any way, concerned or interested in the resolution. The Board recommends the resolution set forth in Item No. 4 for the approval of the members.

For and on behalf of the Board of Directors of **ALPA LABORATORIES LIMITED**

Mahendra Singh Chawla, Whole Time Director

Place: Pigdamber, Rau, Indore

Date: 07th August, 2010

DIRECTOR'S REPORT

Your directors present the 22nd Annual Report of the Company along with the Audited Accounts for the year ended March 31st, 2010.

1. FINANCIAL RESULTS & PERFORMANCE

	Rs. in lacs	Year Ended 31 st Mar, 2010	Year Ended 31 st Mar, 2009
Sales, Other Income & Receipts		9,433.16	11,715.37
Expenditure		9,350.38	11,587.27
Profit (before tax)		82.78	128.11
Less: Prior period Adjustment		18.67	15.06
Less: Deferred Tax liability on Assets		15.00	1.00
Add: Balance Brought Forward From Previous Year		1,959.85	1,921.98
Less: Provision for Income Tax		36.80	76.18
Profit carried to Balance Sheet		2,039.50	1,959.85

2. PAST HISTORY AND FUTURE PROSPECT

The Company posted a turnover of Rs. 9,433.16 lacs for the Financial Year and earned a profit before tax of Rs. 82.78 lacs. The impact of global slowdown continued to affect the company's performance during the year. Even in the difficult market, the company has continued to book a profit as a result of better management, cost efficiencies and strategic planning for margin. The new plant could not commence production during the year, but the management is confident of bringing it into production in the near future.

3. FIXED DEPOSITS

The Company has not accepted any fixed deposits from public during the year under review.

4. DIRECTORS

In accordance with the provisions of Companies Act, 1956 and the provision of the Article of Association of the Company Mr. Mahendra Singh Chawla being director of the Company is liable to retire by rotation and being eligible offers himself for reappointment at the ensuing Annual General Meeting.

During the year, Mr. Kuldeep Singh Parwana ceased to be a director of the company due to his untimely demise. The management of the company offers its condolences to his family and acknowledges his valuable contribution to your company.

Except the above, there has been no change in Board of Director of the company.

5. PARTICULARS OF EMPLOYEES

The particulars of Employee in receipt of the remuneration in excess of the limits laid down in section 217(2A) of the Companies Act 1956, read with the Companies (Particulars of Employees) Rules, 1975 is attached herewith as Annexure I.

6. ENERGY CONSERVATION, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The particulars relating to energy conservation, technology absorption, foreign exchange earnings and outgo, as required to be disclosed under section 217(1)(e) of the Companies Act 1956 read with the Companies (Disclosure of Particulars in the Report of Board of Directors) Rules 1988 are provided in the Annexure II to the Report.

7. RE-CONSTITUTION OF AUDIT COMMITTEE

Pursuant to the Companies Act 1956 and the Listing Agreement, an audit committee exists in the Company and the same was re-constituted on 15th October, 2009; consisting of a non-executive independent director as chairman and 2/3 number of members of total strength of the committee as non-executive independent directors.

8. DESOLUTION OF REMUNERATION COMMITTEE

Upon the untimely demise of Mr. K.S. Parwana, the Remuneration committee dissolved and the Board is in process of appointing a new Independent Director and reconstituting the remuneration committee.

9. DIRECTOR'S RESPONSIBILITY STATEMENT

Pursuant to the requirement under Section 217 (2AA) of the Companies Act, 1956, it is hereby confirmed:

- a) That in the preparation of the annual accounts for the financial year ended 31st March, 2010; the applicable accounting standards have been followed along with proper explanation relating to material departures.
- b) That the directors had selected such accounting policies and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for the year under review.
- c) That the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 1956, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.
- d) That the directors had prepared the accounts for the financial year ended 31st March, 2010, on a "Going Concern" basis.

10. CORPORATE GOVERNANCE

The Board of Directors of the Company have adopted a code of conduct for all board members and senior management of the Company and they declared and affirmed compliance of said code of conduct. Pursuant to Clause 49 of the Listing Agreement, a Report on Corporate Governance along with the Auditor's Certificate of its compliance forms part of the Annual Report.

11. MANAGEMENT DISCUSSION & ANALYSIS**Forward Looking Statements**

Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The Company's actual results, performance or achievements could thus differ materially from those projected in any such forward-looking statements. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events.

Infrastructure

The Company already has a state of the art manufacturing facility at Pigdamber, Indore (Unit-I) where it manufactures a wide range of dosage forms like Injections, Tablets, Ointments and Capsules. An up-gradation of the existing facility in terms of cGMP norms and expansion of capacities has recently been completed. At present the Company is tapping the domestic market, export markets like East & West Africa, Latin America, South East Asia and domestic and international Government Tender business from this facility. The Company also has a state of the art testing laboratory which is further being upgraded to USFDA standards.

A new regulated market compliant tablet manufacturing facility focusing on containment products such as hormonal and anti-cancer formulations is in the completion phase at Unit-II at the Pithampur Industrial Area. The plant is expected to be operational shortly and will be backed by world class manufacturing and testing equipment. The Company expects to offer its facility for regulatory inspections and approvals soon after completion.

Domestic Markets

The Company has a wide range of pharmaceutical products in its portfolio. A focused approach and increased marketing efforts has resulted in an increasingly wider reach. In the coming years, the Company would continue to build its reputation and strong brand equity in order to attain a leadership position. The Company has been successfully marketing human products through a generics distribution model.

International Markets

The Company continues to lay emphasis on its overseas business. The Company works closely with all its overseas partners to sustain and grow its exports. In the last financial year, the Company has expanded its operations in South East Asia, Africa and Latin America. With the commercial production expected to start soon at Unit-II, the company will be ready to take a leap into the regulated markets.

Outlook

Your company remains optimistic about the bright future lying ahead for the company. It will endeavor to grow by building on its strengths for competitive advantage. The Domestic business is becoming more competitive with the entry of newer players from the emerging economies. On the other hand, the government induced changes in select markets and the ongoing consolidation in the industry is bringing forth new challenges in the market place. The generic segment has inherent risks of patent litigation, product liability, continuous development in R&D, capital investment, increasing regulations and compliance related issues, particularly in the developed markets.

Business Strategy

Your company has always endeavored to optimize shareholder value but due to various factors, the company has not been able to achieve

the anticipated levels. However, in the opinion of Directors, after setting up new plant at Pithampur (Unit-II), the product range will be enhanced resulting in a sharp increase in profitability. The new plant shall be fully established by the end of October, 2010 and is estimated to start production by January 2011. The company is deriving its strength from diverse product capability, established client relationship, location advantage and an experienced management team.

Risk Concerns

Uncertainties in business offer opportunities and downside risks. Consequently, your Company recognizes the importance of a well structured system to identify and manage the different elements of risk. Pressure on margins, high raw material prices, availability of substitutes, indiscriminate imports, higher overheads, patent litigation are some factors which could impact adversely especially as we strive to tap into the regulated markets.

Segment wise performance

Your company operates in the single segment of drugs and chemicals.

Internal Control Systems

Internal control procedures of the Company are designed to meet the needs of the Organization's size and complexity of operations. These procedures ensure compliance with various policies, practices and statutes. Internal Audit is carried out of all functional areas through out the year. The Company's Internal Audit function is staffed with qualified and experienced people.

Human Resources and Industrial Relations

The company has given emphasis to upgrading the skills of its technical and marketing personnel. This is in line with its policy of enhancing the individual's growth potential within the framework of corporate goals. The HR policy and practices are constantly reshaped to meet newer demands. Not only better hiring practices, but also improved nurturing practices are in place. Company imparts training towards continuous enhancement of technical and managerial skills. The Directors acknowledge and appreciate the contribution of all employees towards the performance of the company. During the year under review the Company, maintained cordial relationship with all employees and has not laid off any employee in its entire history.

Cautionary Statement

The information and opinion expressed in this report may contain certain forward looking statements which the management believe are true to the best of its knowledge at the time of its preparation. Actual results may differ materially from those either expressed or implied in this report. Important developments that could affect the Company's operations include a downward trend in the industry, rise in input costs, exchange rate fluctuations, and significant changes in political and economic environment, environment standards, tax laws, litigation and labor relations.

12. DISCLOSURES

The Company has made adequate disclosures regarding related party transactions, contingent liabilities, remuneration of directors, and significant accounting policy in the Notes to Accounts as an integral part of the Balance Sheet and Profit & Loss Accounts.

13. STOCK EXCHANGES - COMPLIANCE OF LISTING AGREEMENTS

During the year under review, the Company's shares got listed at The Bombay Stock Exchange Limited and The National Stock Exchange of India Limited. The Company has paid the listing fees to all the Stock Exchanges.

14. AUDITORS

M/s. C. H. Padliya & Co., Chartered Accountants, Auditors of your Company retires from the office of the Auditors and are eligible for re-appointment. The Company has received a certificate from them to the effect that the re-appointment if made will be within the limit prescribed under Section 224 (1) of the Companies Act, 1956.

15. AUDITORS REPORT

The Report of Auditors of the Company for the year under reference has two comments.

In reference to point 4(vi) of their report in reference to the netting off of the interest earned against interest paid in the current year, but not in the previous year, the management view is that the netting off of interest is not restricted by any provision of the Act, Rule, Regulation or Accounting Standard. Additionally, it does not impact the profit of the company in any way.

In reference to point (ix)(c) of the annexure to their report in reference to irregular payment of statutory dues, as further clarified in the same report, the management has made appeals against the demand of statutory dues in question at various forums and the hearings for these appeals are pending.

16. COMPLIANCE OF ACCOUNTING STANDARD

As per clarification given in Sub Para (iv) of Para 3 of Auditors' Report, Company has complied with all applicable Accounting Standards as per provision of section 211 (3C) of the Companies Act 1956.

17. APPRECIATION

Your directors would like to take this opportunity to record their appreciation of the valuable services rendered by all employees of the Company and to the Company's shareholders, customers, suppliers and other associates for their continued support.

For and on behalf of the Board of Directors of **ALPA LABORATORIES LIMITED**

Purushottam R. Patel

Managing Director

Place: Pigdamber, Rau, Indore

Date: 21st May, 2010

Mahendra Singh Chawla

Whole Time Director

Pravin C. Shah

Whole Time Director

ANNEXURE I

(Annexed to and forming part of the Directors' Report for the year ended 31st March, 2010)

Statement of Particulars of Employees as per Section 217(2A) of the Companies act, 1956 Read with the Companies (Particulars of Employees) Rules, 1975 as amended

NAME AGE	DESIGNATION	GROSS REMUNERATION	QUALIFICATIONS EXPERIENCE	DATE OF JOINING	PREVIOUS EMPLOYER
Purushottam R. Patel 76 years	Chairman & Managing Director	Rs. 2700000	B.Sc. (Honors) 53 Years	Since Incorporation.	Partner, Alpa Laboratories
Mahendra Singh Chawla 68 years	Whole Time Director	Rs. 2700000	B.Sc. 43 Years	Since Incorporation.	Partner, Alpa Laboratories
Pravin C. Shah 62 Years	Whole Time Director	Rs. 2460000	B.Sc. 33 Years	Since Incorporation.	Partner, Alpa Laboratories

Notes:

1. The nature of employment is Contractual.
2. The above employees are also Directors of the Company but they are not related to any other Directors of the Company.
3. Information about Qualifications and Last employment are based on particulars furnished by the employee.
4. All above directors are shareholders of the Company and hold more than 2% each of the total issued shares of the Company.

ANNEXURE II

(Annexed to and forming part of the Directors' Report for the year ended 31st March, 2010)

Companies (Disclosure of particulars in the report of the Board of Directors) – Rules 1988

Particulars in respect of :

A. Conservation of Energy

The total energy consumption and energy consumption per unit as per Form A given herein below:

FORM A

FORM OF DISCLOSURE OF PARTICULARS WITH RESPECT TO CONSERVATION OF ENERGY

	Year Ended 31 st Mar, 2010	Year Ended 31 st Mar, 2009
POWER CONSUMPTION		
i. Electricity		
a. Purchased Units	1623100	1660840
• Total Amount (Rs. in lacs)	80.52	81.76
• Rate/Unit (Rs.)	4.96	4.92
b. Own Generation Units		
• Through Diesel Generator Units	506	468
• Total Amount (Rs. in lacs)	0.09	0.08
• Cost Per Unit (Rs.)	17.79	17.09
ii. Coal	-	-
iii. Furnace Oil (MT)	104.65	115.25
iv. Others/ Internal Generation	-	-
CONSUMPTION OF ENERGY		
i. Electricity (Units Purchased & Own Generated)	1623606	1661308

B. Technology Absorption

There has been no specific scope for technology absorption; still the Company is updating the existing machines as much as possible for better productivity and to introduce latest techniques and trends.

C. Foreign Exchange earning and outgo

	Rs. in lacs	Year Ended 31 st Mar, 2010	Year Ended 31 st Mar, 2009
Earning on Account of Export		973.03	691.43
Outgoings			
• For Raw Material		46.40	77.97

• For Capital Goods	-	-
• For Bank Charges	4.68	1.88
• For Travel Expenses	1.35	1.32

CORPORATE GOVERNANCE REPORT

The detailed report on implementation by the Company of the Corporate Governance Code as incorporated in Clause 49 of the Listing Agreement with Stock Exchanges is set out below:

1. Corporate Governance Philosophy

Our corporate governance policies recognize the accountability of the Board and importance of its decisions to all constituents, including investors, customers, employees and regulatory authorities and to demonstrate to shareholders who are the ultimate beneficiaries of our economic activities. The functions of the Board and the Executive Management are well defined and are distinct from one another.

2. Board of Directors

The Board of Directors of Alpa Laboratories Limited (the Company) comprised of Promoter Executive Chairman & Managing Director, two Promoter Executive Directors and two Independent Non-executive Directors who have wide and varied experience in different disciplines of corporate functioning.

The composition and category of the Board of Directors as on March 31, 2010 was as follows:

Category	Name of Director
Promoter Executive Chairman & Managing Director	Mr. Purushottam R. Patel
Promoter Executive Directors	Mr. Mahendra Singh Chawla, Mr. Pravin C Shah
Independent Non-Executive Directors	Mr. Sampat Lal Chaplot Mr. Sharad Chand Lunawat Mr. Kuldeep Singh Parwana (Ceased on 15/Oct/2009)

The Company has no pecuniary relationship or transaction with any of the Independent Non-executive Directors.

A brief write up about the Directors coming up for re-appointment has been provided in the notice to the Shareholders.

The Board of Directors met four times during the period under review on 29/May/2009, 30/Jul/2009, 30/Oct/2009 and 28/Jan/2010.

Attendance of each Director at the meeting of the Board of Director held during the year and the last Annual General Meeting and also the number of Board of Directors or Committee meetings of which he is a member/ chairman is as under:

Name of Director	Attendance Particulars		No of Directorships in domestic public limited companies (including this Company)		No of Committee Memberships ¹ in domestic public limited companies (including this Company)	
			As Chairman	As Director	As Chairman	As Member
Mr. Purushottam R. Patel	Board Meetings 4	Last AGM Yes	1	-	-	2
Mr. Mahendra Singh Chawla	4	Yes	-	1	-	1
Mr. Pravin C Shah	4	Yes	-	1	-	-
Mr. Sampat Lal Chaplot	4	Yes	-	1	3 ²	-
Mr. Sharad Chand Lunawat	3	Yes	-	1	-	1
Mr. Kuldeep Singh Parwana ³	2	Yes	-	1	-	2

¹None of the directors is a member of more than ten committees or acting as Chairman of more than five committees across all companies in which he is a director

²Ceased to be chairman of Remuneration committee from 15/Oct/2009

³Ceased to be member of committee from 15/Oct/2009

3. Audit Committee (see term of reference)

The Company has complied with the requirements of Section 292A of the Companies Act, 1956 and Clause 49 of the Listing Agreement relating to the composition and terms of reference of the Audit Committee. The Committee comprised of 2 Independent Non-executive Directors (1 as the Chairman) and 1 Executive Director. The committee was reconstituted on 15/Oct/2009 with the same composition of 2 Independent Non-executive Directors (1 as Chairman) and 1 Executive Director.

The Terms of Reference of the Audit Committee are in accordance with paragraphs C and D of Clause 49 (11) of the Listing Agreement and as specified by the Board of Directors of the Company. The responsibilities of the Committee include financial reporting, standards compliance and review of financial policies of the Company and also to recommend the appointment of Statutory Auditors and Internal Auditors and to fix their remuneration. The Audit Committee evaluates internal audit policies, plans and procedures and reviews other functions through various internal audit reports. The committee also reviews all the unaudited and audited financial results before the submission to the Board. The Chairman of the Audit Committee was present at the last Annual General Meeting (AGM) of the Company held on 30th July, 2009. The Audit Committee met four times during the year on 29/May/2009, 30/Jul/2009, 30/Oct/2009 and 08/Jan/2010. The members of the Audit Committee and their attendance are given below: